Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | SNCA | P37840 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150555 | 0.89 | KDR (0.54) | KDRAURKAFGFR1CHEK1 | |
| SCHEMBL4150561 | 0.89 | KDR (0.54) | KDRAURKAFGFR1CHEK1 | |
| SCHEMBL4136114 | 0.89 | KDR (0.55) | KDRAURKAFGFR1CHEK1SNCA | |
| SCHEMBL4136121 | 0.89 | KDR (0.55) | KDRAURKAFGFR1CHEK1SNCA | |
| SCHEMBL4144045 | 0.88 | KDR (0.67) | KDRAURKAFGFR1CHEK1SNCA | |
| SCHEMBL4144047 | 0.88 | KDR (0.67) | KDRAURKAFGFR1CHEK1SNCA | |
| SCHEMBL4150087 | 0.85 | KDR (0.50) | KDRAURKAFGFR1CHEK1SNCA | |
| SCHEMBL4150084 | 0.85 | KDR (0.50) | KDRAURKAFGFR1CHEK1SNCA | |
| SCHEMBL6426090 | 0.84 | KDR (0.51) | KDRAURKAFGFR1CHEK1SNCA | |
| SCHEMBL6427311 | 0.84 | KDR (0.47) | KDRAURKAFGFR1CHEK1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | KDR 1044/4885AURKA 710/4885FGFR1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.